Header cover image

Investing Ideas
/
U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential

U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential

Results

11

1 new

Stocks with plenty of capacity to fund future growth

11 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	INCY Incyte	US$71.05	-11.7%	33.1%	US$13.6b	US$78.05	PE421.4x	E46.3%	n/a
	NBIX Neurocrine Biosciences	US$123.29	-1.8%	11.1%	US$12.1b	US$163.46	PE32.3x	E29.6%	n/a
	CORT Corcept Therapeutics	US$56.09	-0.6%	121.3%	US$5.7b	US$74.90	PE41.8x	E41.0%	n/a
	KRYS Krystal Biotech	US$178.10	-3.3%	74.6%	US$5.1b	US$207.78	PE97.8x	E41.2%	n/a
	ADMA ADMA Biologics	US$21.37	-0.5%	441.0%	US$4.9b	US$23.45	PE74.1x	E30.5%	n/a
	VCEL Vericel	US$57.26	3.2%	61.3%	US$2.8b	US$59.38	PE796.6x	E51.4%	n/a
	ACAD ACADIA Pharmaceuticals	US$16.27	-7.5%	-26.0%	US$2.7b	US$25.11	PE21.1x	E28.4%	n/a
	LGND Ligand Pharmaceuticals	US$111.56	-8.6%	87.5%	US$2.1b	US$140.25	PE46.6x	E35.5%	n/a
	HRMY Harmony Biosciences Holdings	US$32.79	-3.1%	15.1%	US$1.9b	US$47.11	PE15.3x	E32.8%	n/a
	CDXC ChromaDex	US$7.50	7.0%	417.2%	US$575.7m	US$7.96	PE386.6x	E81.8%	n/a
	BSEM New BioStem Technologies	US$12.04	-48.5%	301.2%	US$211.1m	US$32.50	PE12.6x	E33.8%	n/a

Page 1 of 1